Empowering Immuno Oncology
Feromics, Inc. is a discovery phase cancer immunotherapy technology company focused on the development of novel intelligent chimeric antigen receptor (iCAR™) constructs for hematological malignancies and solid tumors. Our proprietary and revolutionary Intelligent Design ID™ platform enables the design of novel CAR constructs with exhaustion-resistant and serial killing capabilities that effectively target and destroy cancer cells. At Feromics, our mission is to create and lead the next revolution in precision-based cancer treatment by providing patients with another chance at life.
Feromics is leveraging the power of its discovery platform to deliver a homogenous product of immune cells that are exhaustion-resistant and exhibit strong and sustained cytotoxicity and metabolic activity against cancer cells. By accurately profiling, identifying, isolating, and analyzing these unique immune cells, Feromics is discovering new mechanisms that can be targeted for designing novel immunotherapies that overcome current limitations and provide cancer patients with another chance at life.
Utilizing our proprietary and revolutionary Intelligent Design ID™ platform for function to transcriptomics (functionomic) workflow and construct design, Feromics has developed a pipeline of novel iCAR constructs. These constructs include novel design of signaling and co-stimulatory pro-survival domains, thus enhancing the therapeutic potential of NK, macrophages, and T-cells in their ability to combat both solid and hematological malignancies effectively and will be used to improve existing immunotherapies as well as develop the next-generation of iCAR therapies.
